癌症支持治疗药物市场规模、份额和成长分析（按治疗层级、应用、分销管道和地区）- 产业预测 2025-2032

癌症支持治疗药物市场规模预计到 2023 年将达到 217.5 亿美元，并从 2024 年的 224 亿美元增长到 2032 年的 283.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 3.0%。

全球癌症支持护理药物市场对于减轻癌症治疗的副作用和改善患者的生活品质至关重要。癌症发病率的上升、人口老化以及癌症治疗的突破性进展正在推动该领域的显着增长。止吐药、止痛药和补血药等支持性护理药物对于控制噁心、疼痛和血球数低等副作用至关重要。正在进行的研究和开发重点是开发更有针对性的治疗方法，製药公司之间的合作正在扩大将支持治疗与癌症治疗相结合的治疗选择。随着以患者为中心的照护变得越来越突出，以及人们认识到治疗期间保持生活品质的重要性，推动创新并提高患者的舒适度，对这些药物的需求预计将继续增长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 宏观经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 专利分析

癌症支持治疗药物市场规模（按治疗层级和复合年增长率） (2025-2032)

• 市场概况
• 颗粒细胞增生因子（G-CSF）
• 促红血球生成素刺激剂 (ESA)
• 止吐药
• 双磷酸盐
• 阿片类药物
• 非类固醇消炎剂(NSAID)

癌症支持治疗药物市场规模（按应用划分）及复合年增长率（2025-2032）

• 市场概况
• 化疗引起的噁心和呕吐 (CINV)
• 化疗引起的贫血
• 化疗引起的嗜中性白血球低下症
• 骨转移
• 癌症痛
• 其他的

癌症支持治疗药物市场规模（按分销管道和复合年增长率）（2025-2032）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

癌症支持治疗药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Amgen Inc.（USA）
• Merck & Co., Inc.（USA）
• Johnson & Johnson Services, Inc.（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche AG（Switzerland）
• Sanofi（France）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Helsinn Healthcare（Switzerland）
• Heron Therapeutics, Inc.（USA）
• Acacia Pharma Group Plc（UK）
• Sun Pharmaceutical Industries Ltd.（India）
• Celldex Therapeutics（USA）
• Ipsen Pharma（France）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Mylan NV（USA）
• Dr. Reddy's Laboratories Ltd.（India）
• Eli Lilly and Company（USA）

结论和建议

Cancer Supportive Care Drugs Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.4 billion in 2024 to USD 28.38 billion by 2032, growing at a CAGR of 3.0% during the forecast period (2025-2032).

The global market for cancer supportive care drugs is pivotal in alleviating the adverse effects of cancer treatments and enhancing patients' quality of life. With rising cancer incidence, an aging population, and breakthroughs in cancer therapies, this sector has experienced significant growth. Supportive care drugs, including antiemetics, analgesics, and hematopoietic agents, are essential in managing side effects such as nausea, pain, and low blood cell counts. Ongoing research and development efforts are focused on creating more targeted therapies, and collaborations among pharmaceutical companies are expanding treatment options to integrate supportive care with cancer treatments. As the focus on patient-centered care intensifies and the importance of maintaining quality of life during treatment gains recognition, demand for these drugs is expected to continue to grow, driving innovation and enhancing patient comfort.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Supportive Care Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Supportive Care Drugs Market Segments Analysis

Global Cancer Supportive Care Drugs Market is segmented by Therapeutic Class, Application, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into Granulocyte Colony-Stimulating Factors (G-CSFs), Erythropoiesis-Stimulating Agents (ESAs), Antiemetics, Bisphosphonates, Opioids and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Based on Application, the market is segmented into Chemotherapy-Induced Nausea and Vomiting (CINV), Chemotherapy-Induced Anemia, Chemotherapy-Induced Neutropenia, Bone Metastasis, Cancer Pain and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Supportive Care Drugs Market

The escalating incidence of cancer worldwide significantly drives the demand for cancer supportive care drugs. As more patients receive treatments such as chemotherapy, radiation therapy, and targeted therapies, the necessity to manage the adverse effects associated with these procedures becomes increasingly critical. Supportive care drugs play a vital role in enhancing patients' quality of life by alleviating symptoms such as nausea, pain, anemia, and fatigue, which often accompany cancer treatments. Consequently, the growing population of cancer patients seeking effective relief options underscores the importance of these drugs in the therapeutic landscape, further propelling market growth in the cancer supportive care segment.

Restraints in the Cancer Supportive Care Drugs Market

The high cost of cancer supportive care drugs presents a significant challenge in the market, potentially limiting their accessibility and usage. For many cancer patients, especially those in regions with limited healthcare insurance or inadequate government-funded healthcare programs, the financial burden can be overwhelming. This steep pricing may deter patients from utilizing these essential medications, which are crucial for managing treatment side effects. Consequently, this economic restraint can hinder effective cancer care, ultimately impacting patients' quality of life and their ability to cope with the rigorous demands of their treatment regimen.

Market Trends of the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs market is experiencing a significant trend towards personalized supportive care, driven by advancements in individualized cancer treatments. As therapies become more tailored to specific cancer types and patient characteristics, there is a growing demand for supportive care medications designed to alleviate unique side effects such as chemotherapy-induced nausea, vomiting, pain, fatigue, and anemia. This targeted approach enhances patient quality of life and fosters better treatment adherence, ultimately improving overall outcomes. With the increasing recognition of the importance of supportive care in holistic cancer management, the market is poised for robust growth, reflecting the evolving needs of patients and healthcare providers.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Cancer Supportive Care Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• Granulocyte Colony-Stimulating Factors (G-CSFs)
• Erythropoiesis-Stimulating Agents (ESAs)
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Global Cancer Supportive Care Drugs Market Size by Application & CAGR (2025-2032)

• Market Overview
• Chemotherapy-Induced Nausea and Vomiting (CINV)
• Chemotherapy-Induced Anemia
• Chemotherapy-Induced Neutropenia
• Bone Metastasis
• Cancer Pain
• Others

Global Cancer Supportive Care Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cancer Supportive Care Drugs Market Size & CAGR (2025-2032)

• North America (Therapeutic Class, Application, Distribution Channel)
  • US
  • Canada
• Europe (Therapeutic Class, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Healthcare (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acacia Pharma Group Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations